Dupilumab moves onto the next phase in trials

Dupilumab, the first systemic drug for eczema

Eczema treatments and drug trials are in works by several pharmaceutical companies. Some of these drugs focus on tracking strictly the inflammatory component, and some on the itch. Another experimental drug moving ahead is Dupilumab, which targets proteins that trigger allergic response, which means it may hold some hope in Asthma and Rhinitis cases as well.

Currently, the only systemic therapy available for eczema is immunosuppressants, which come with major side effects, especially in kids. Although this drug is targeted for adults, it open up doors for new methods in kids treatments as well.

Progress is progress!!! It gives me hope that my son will someday have a cure for eczema, or atleast options without side effects to manage his condition.


Also Read – ZPL-389 Shows Positive Results For Atopic Dermatitis

Crisaborole Gets FDA Approval For Treatment of Atopic Dermatitis

Leave a Reply

Your email address will not be published. Required fields are marked *